financetom
Business
financetom
/
Business
/
Shein's IPO to be delayed to second-half after US 'de minimis' repeal, FT reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Shein's IPO to be delayed to second-half after US 'de minimis' repeal, FT reports
Feb 13, 2025 9:48 PM

(Reuters) -Fast-fashion group Shein's plans to list in the UK stock market are likely to be postponed to the second-half of this year after Donald Trump's move to close so-called "de minimis" rules, the Financial Times reported on Friday.

Shein was aiming to go public in London in the first-half of this year, assuming it secured approvals from regulators in the UK and China, Reuters reported last month.

The company's business prospects have come under a cloud in recent days after the Trump administration said it would close the de minimis duty exemption in the United States, ending an import rule that had helped Shein keep prices low.

The removal of the exemption could hurt Shein's profitability and push up product prices in the U.S., which is its biggest market, analysts and industry experts had earlier said.

The fast-fashion retailer previously told investors that a London listing could happen as soon as this Easter, FT said, citing people with knowledge of the discussions.

Shein did not immediately respond to a Reuters' request for comment.

The removal of de minimis is part of Trump's imposition of an additional 10% tariff on China, in what he called an "opening salvo" in a clash between the world's two largest economies.

Shein and rival Temu together probably accounted for more than 30% of all packages shipped to the U.S. each day under the de minimis provision, the U.S. congressional committee on China said in a 2023 report. The measure exempted shipments of less than $800 from import duties.

Last week, Reuters reported that Shein was set to cut its valuation in a potential listing to around $50 billion, nearly a quarter less than the company's fundraising value of $66 billion in 2023, amid growing headwinds.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma
Jun 14, 2024
07:48 AM EDT, 06/14/2024 (MT Newswires) -- BeiGene ( BGNE ) said Friday that preliminary data from a phase 3 study of Brukinsa in combination with venetoclax to treat patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma showed promising efficacy and tolerability. The company said the overall response rate among the 65 response-evaluable patients treated with the combination was...
Colonial allocates Cycle 36 shipments on distillate Line 20
Colonial allocates Cycle 36 shipments on distillate Line 20
Jun 14, 2024
June 14 (Reuters) - Colonial Pipeline Co is allocating space for Cycle 36 shipments on Line 20, which carries distillates from Atlanta to Nashville, Tennessee, the company said in a notice sent to shippers on Friday. * Committed information will be available on June 17, the pipeline operator said. * The company generally announces allocations when nominations, or requests, for...
VersaBank Secures Final U.S. Regulatory Approval for U.S. Bank Purchase
VersaBank Secures Final U.S. Regulatory Approval for U.S. Bank Purchase
Jun 14, 2024
07:46 AM EDT, 06/14/2024 (MT Newswires) -- VersaBank ( VBNK ) said on Friday that it secured approval from the Office of the Comptroller of the Currency for the proposed acquisition of Minnesota-based Stearns Bank Holdingford. The U.S. Federal Reserve recently approved the proposed deal. Stearns Holdingford is an independent OCC-chartered national bank with US$79 million in assets located in...
Greenwich LifeSciences' CEO Acquires $2.5 Million in Shares
Greenwich LifeSciences' CEO Acquires $2.5 Million in Shares
Jun 14, 2024
07:46 AM EDT, 06/14/2024 (MT Newswires) -- Greenwich LifeSciences ( GLSI ) said Friday it has agreed to sell about 175,000 shares of common stock for $14.30 per share in a private placement to Chief Executive Snehal Patel. The deal, to take place around Tuesday, is expected to generate $2.5 million for the company. Greenwich plans to use net proceeds...
Copyright 2023-2026 - www.financetom.com All Rights Reserved